23-04-2009Latest results - Q1 2009

Pharmaceuticals delivers strong underlying growth in first quarter of 2009 as Novartis continues to rejuvenate product portfolio

19-03-2009Sandoz and Novartis in the fight against tuberculosis

The war against tuberculosis has been fought for well over a century yet it continues to claim nearly two million victims per year – or one person every 15 seconds. Given that horrific figure, global awareness of this killer disease remains astonishingly low.

18-02-2009Barleben (Germany)

A shining example of successful locational policy

13-02-2009Sandoz receives European Commission approval for biosimilar filgrastim

Third biosimilar medicine further reinforces pioneer position in field

28-01-2009Novartis Annual Results and Q4 2008

Novartis increases dividend by 25% based on strong 2008 results from strategic healthcare portfolio

27-11-2008Creating "headroom" for healthcare systems

Attendees at a Sandoz event in Berlin, Germany, hear about the financial benefits of biosimilars - and why Sandoz is the leader in this field.

21-11-2008Sandoz gets positive opinion for biosimilar filgrastim

Sandoz has received a positive opinion from European regulators for its third biosimilar medicine, filgrastim, marking another important milestone in its efforts to bring affordable high-quality biopharmaceuticals to patients worldwide.

20-10-2008Latest Results Q3 2008

Novartis delivers sustained strong performance in first nine months of 2008 underpinned by accelerating growth in pharmaceuticals

03-09-2008Sandoz receives FDA approval

for Omnitrope® Pen 10 with liquid cartridge

11-06-2008Leading experts gather in Spain to discuss key aspects of tuberculosis control

Tuberculosis kills almost two million people a year – but it is curable, and its spread can be stopped